{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:02:48Z","timestamp":1761894168776},"reference-count":71,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,9,10]]},"abstract":"<jats:p>Marginal-zone lymphomas comprise the mucosa-associated lymphoid tissue (MALT) type (extranodal marginal-zone lymphoma [EMZL]), the nodal marginal zone B-cell lymphoma (NMZL) and the splenic MZL (SMZL). EMZL is relatively common, whereas the remaining two entities are relatively rare disorders. EMZL, especially in its gastric localization, is the most studied MZL, and there are many data both on the underlying genetic lesions and on the role of infectious agents. These data have determined unique approach among all other lymphoma subtypes: the possibility of treating a subset of patients with antibiotics alone as first line of treatment. Indeed, there is compelling evidence that histologic regressions can be achieved in most gastric MALT lymphomas by eradicating Helicobacter pylori infection. However, molecular follow-up studies showed the persistence of the malignant clone in half of the cases in histologic remission after antibiotic treatment and transient, either histologic or molecular, relapses have been reported, too. Hence, a careful long-term follow-up is mandatory after antibiotic treatment. Radiotherapy, chemotherapy, anti-CD20 monoclonal antibodies are effective alternative therapies. The precise role of surgical resection should be redefined in view of the encouraging results of conservative approaches. Differently from EMZL, both SMLZ and NMZL often present with disseminated disease at diagnosis. The therapeutic approach comprises splenectomy, for SMZL, and chemotherapy, but with no consensus about the best treatment. This review addresses the current knowledge on the clinical features and therapeutic approaches for the individual MZLs.<\/jats:p>","DOI":"10.1200\/jco.2005.05.018","type":"journal-article","created":{"date-parts":[[2005,9,9]],"date-time":"2005-09-09T04:07:52Z","timestamp":1126238872000},"page":"6415-6420","source":"Crossref","is-referenced-by-count":88,"title":["State-of-the-Art Therapeutics: Marginal-Zone Lymphoma"],"prefix":"10.1200","volume":"23","author":[{"given":"Francesco","family":"Bertoni","sequence":"first","affiliation":[{"name":"From the Laboratory of Experimental Oncology; and the Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[{"name":"From the Laboratory of Experimental Oncology; and the Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"BIB1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"BIB3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"BIB4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.410"},{"key":"BIB6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1279"},{"key":"BIB7","unstructured":"Thieblemont C, Dumontet C, Salles G, et al: Mucosa-associated lymphoid tissue (MALT) -lymphoma are disseminated disease in 1\/3 of the patients. Ann Oncol 10:25,1999 (suppl 3)"},{"key":"BIB8","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008392022152"},{"key":"BIB9","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058869"},{"key":"BIB10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2215"},{"key":"BIB11","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64988-7"},{"key":"BIB12","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65012-2"},{"key":"BIB13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403501"},{"key":"BIB14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3236"},{"key":"BIB15","doi-asserted-by":"crossref","unstructured":"Streubel B, Lamprecht A, Dierlamm J, et al: T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101:2335,2002-2339,","DOI":"10.1182\/blood-2002-09-2963"},{"key":"BIB16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403644"},{"key":"BIB17","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64630-5"},{"key":"BIB18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.1182"},{"key":"BIB19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.4014"},{"key":"BIB20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840601)53:11<2515::AID-CNCR2820531125>3.0.CO;2-C"},{"key":"BIB22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00651-4"},{"key":"BIB23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301803"},{"key":"BIB24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803193381205"},{"key":"BIB25","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91409-F"},{"key":"BIB26","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70088-J"},{"key":"BIB27","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(00)80233-6"},{"key":"BIB28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh102"},{"key":"BIB29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.083"},{"key":"BIB30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031887"},{"key":"BIB31","doi-asserted-by":"crossref","unstructured":"Al-Saleem T, Al-Mondhiry H: Immunoproliferative small intestinal disease (IPSID): A model for mature B-cell neoplasms. Blood 105:2274,2004-2280,","DOI":"10.1182\/blood-2004-07-2755"},{"key":"BIB32","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9322502"},{"key":"BIB33","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.3.297"},{"key":"BIB34","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80904-0"},{"key":"BIB35","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-2-199907200-00003"},{"key":"BIB36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.1.19"},{"key":"BIB37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07424.x"},{"key":"BIB39","unstructured":"Hancock B, Linch D, Delchier J, et al: Chlorambucil versus observation after anti-Helicobacter therapy in low-grade gastric lymphoma: Results of the international LY03 trial. Ann Oncol 16:57,2005, (suppl 5; abstr 74)"},{"key":"BIB40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.18.1350"},{"key":"BIB41","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.4.454"},{"key":"BIB42","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709050889"},{"key":"BIB43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2541"},{"key":"BIB44","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.11.1656"},{"key":"BIB45","unstructured":"Copie-Bergman C, Capella C, Motta T, et al: Validation of the GELA scoring system for evaluating gastric biopsies from patients with malt lymphoma following eradication of Helicobacter pylori. Ann Oncol 16:94,2005, (suppl 5; abstr 194)"},{"key":"BIB46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1600"},{"key":"BIB48","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000035680"},{"key":"BIB49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1916"},{"key":"BIB50","doi-asserted-by":"crossref","unstructured":"Yahalom J: MALT lymphomas: A radiation oncology viewpoint. Ann Hematol 80:B100,2001-B105, (suppl 3)","DOI":"10.1007\/PL00022769"},{"key":"BIB51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.085"},{"key":"BIB54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2524"},{"key":"BIB55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05460.x"},{"key":"BIB56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20237"},{"key":"BIB57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.117"},{"key":"BIB58","unstructured":"Jager G, Hofler G, Linkesch W, et al: Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica 89:ECR01,2004,"},{"key":"BIB59","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg492"},{"key":"BIB60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"BIB61","doi-asserted-by":"crossref","unstructured":"Martinelli G, Laszlo D, Ferreri AJ, et al: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol , 2005","DOI":"10.1200\/JCO.2005.08.128"},{"key":"BIB62","unstructured":"Catovsky D, Matutes E: Splenic lymphoma with circulating villous lymphocytes\/splenic marginal-zone lymphoma. Semin Hematol 36:148,1999-154,"},{"key":"BIB63","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x"},{"key":"BIB64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.1950"},{"key":"BIB65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654"},{"key":"BIB66","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.010"},{"key":"BIB67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2160"},{"key":"BIB68","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00981-1"},{"key":"BIB69","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.005"},{"key":"BIB70","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123555"},{"key":"BIB71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013376"},{"key":"BIB72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.008"},{"key":"BIB73","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403443"},{"key":"BIB74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1711"},{"key":"BIB75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2486"},{"key":"BIB76","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881015)62:8<1531::AID-CNCR2820620814>3.0.CO;2-A"},{"key":"BIB77","doi-asserted-by":"publisher","DOI":"10.1007\/BF02780533"},{"key":"BIB79","unstructured":"Arcaini L, Paulli M, Boveri E, et al: Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 88:80,2003-93,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.05.018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:34:17Z","timestamp":1683200057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.05.018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,10]]},"references-count":71,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2005,9,10]]}},"alternative-id":["10.1200\/JCO.2005.05.018"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.05.018","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,10]]}}}